(NASDAQ: EYPT) Eyepoint Pharmaceuticals's forecast annual revenue growth rate of 78.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Eyepoint Pharmaceuticals's revenue in 2026 is $42,340,000.On average, 15 Wall Street analysts forecast EYPT's revenue for 2026 to be $772,487,550, with the lowest EYPT revenue forecast at $0, and the highest EYPT revenue forecast at $3,911,696,145. On average, 13 Wall Street analysts forecast EYPT's revenue for 2027 to be $6,374,450,366, with the lowest EYPT revenue forecast at $389,431,083, and the highest EYPT revenue forecast at $16,429,123,809.
In 2028, EYPT is forecast to generate $22,222,573,465 in revenue, with the lowest revenue forecast at $4,316,194,502 and the highest revenue forecast at $85,105,262,160.